ClinicalTrials.gg
RecruitingNCT07318688Updated Aug 11, 2026

Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain

A Phase 3 interventional study of HMI-115 and Placebo in Endometriosis, sponsored by Hope Medicine (Nanjing) Co., Ltd. Recruiting at 5 sites in China. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Hope Medicine (Nanjing) Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Endometriosis with a site in China — 16 open to participants now, 17 under way, 2 of them phase 3. Endometriosis · China.

Planned enrollment
2nd of 28
540 · median 161
Started
2026
with 5 others
Phase 3
6 of 47
2 open now
Primary completion
2028-03
later than 12 of 16 live
Registered
39th of 47
by date
Lead sponsor
2 of 47
Hope Medicine (Nanjing) Co., Ltd

Among the 47 studies in Endometriosis with a site in China, this one is the 2nd largest by planned enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 12 of the 16 other live ones, and was the 39th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

16 of the 47 studies in Endometriosis with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Endometriosis with a site in China, or all of them as a file.
02

Study summary

A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension

03

Conditions studied

  • Endometriosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Premenopausal female subjects, between 18 and 49 years of age, inclusive.
  • 2. Has a surgical diagnosis of endometriosis (laparoscopy or laparotomy) as documented by medical records within 10 years before screening.
  • 3. Has a Composite Pelvic Signs and Symptoms Score total score of ≥ 6 at screening with a score of at least 2 for DYS and at least 2 for NMPP.
  • 4. Subject has reported "moderate" or "severe" for her endometriosis-associated DYS AND NMPP before randomization.
  • 5. Subject has at least two consecutive regular menstrual cycle (i.e. 21 to 35 days in duration) prior to randomization.
  • 6. Subject agrees to use required (nonhormonal) methods during the entire length of participation in the study and agrees to avoid pregnancy from signing the until 12 weeks after the last dose.
  • 7. Subject agrees to use only those rescue analgesic medications permitted by the protocol during the Screening, Treatment and Posttreatment follow-up Periods for her endometriosis-associated pain.
  • 8. Criteria for Extension Treatment Period:Subject who completes treatment of the placebo-controlled double-blind treatment period and assessments at Week 24.

Exclusion criteria

Exclusion Criteria:

  • 1. Subject who is pregnant or breastfeeding or is planning a pregnancy during the study period or is less than 6 months post-partum or 3 months post-abortion at the time of entry into the Screening Period or pregnancy before randomization.
  • 2. Subject has an intra-uterine device (IUD). Subject is eligible if she removes the IUD 1 month before screening.
  • 3. Subject has chronic pelvic pain that is not caused by endometriosis (e.g., interstitial cystitis, irritable bowel syndrome) or has any other chronic pain syndrome (e.g., fibromyalgia, chronic back pain, myofascial pain syndrome, chronic headaches) that requires chronic analgesic or other chronic therapy, which would interfere with the assessment of endometriosis-associated pain.
  • 4. Subject with a current history of undiagnosed abnormal genital bleeding.
  • 5. Subject with history of hysterectomy and/or bilateral oophorectomy.
  • 6. Subject has had surgery for endometriosis within 6 weeks prior to entry into the Screening Period.
  • 7. Subject has previous history of a severe, life-threatening or other significant sensitivity to any opioids or non-steroidal anti-inflammatory drugs (NSAIDS) or any to their use such as gastrointestinal ulcer or bleeding.
  • 8. Subject with known to any of the IMP ingredients.
  • 9. Subject has an estimated (eGFR) of \< 60mL/min/1.73 m2 at Screening Period.
  • 10. Subject is currently participating in or has participated in an interventional clinical study with an compound or device within 30 days prior to the start of Screening Period or 5 half-lives, whichever is longer.
  • 11. Subject who has been exposed to HMI-115 treatment.
  • 12. Subject has used medications such as hormones, analgesics, medications associated with bone loss, products that affect PRL levels, etc. within specific time window before Screening.
  • 13. Subject has clinically significantly abnormal laboratory tests at Screening Period, including:

    1. (ALT/SGPT), or aspartate aminotransferase (AST/SGOT) ≥200% of the , or total (unless known diagnosis of Gilbert's syndrome) ≥ 150% of the upper limit of normal range.
    2. \< 100 g/L, \< 1.5×109/ L, count \< 100×109/ L.
  • 14. Subject has clinically significantly abnormal laboratory tests at Screening Period, including: Neutrophil count \< 1.5×109/ L, Platelet count \< 100×109/ L.
  • 15. Subject has abnormal , or ECG with > 450 msec at Screening Period.
  • 16. Subject has a history or current has except for treated basal cell carcinoma and cutaneous squamous cell carcinoma of the skin.
  • 17. Subject is using any systemic for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the study.
  • 18. Subject has any of the following conditions within the last 6 months before Screening:

    1. Myocardial infarction, stroke, unstable angina or .
    2. Classified as being in Class III or IV.
  • 19. Subjects with body weight greater than 300 pounds or 136 kilograms.
  • 20. Any other conditions in the Investigator's opinion that prevent the subject from participating.
  • 21. Criteria for Extension Treatment Period: Subjects entering the follow-up period after treatment: subjects with a BMD decrease of ≥ 8.0% or Z-value ≤ -2.0 in any part of the lumbar spine, femoral neck, or total hip compared to baseline.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    HMI-115_120mg

    120mg, Once Every 2 weeks, subcutaneously injection,total of 26 injections (Week 0 to Week 52) or total of 14 injections (Week 24 to Week 52/Extension Treatment Period of Placebo )

    Drug: HMI-115

  • Experimental
    HMI-115_240mg

    240mg, Once Every 2 weeks, subcutaneously injection,total of 26 injections (Week 0 to Week 52) or total of 14 injections (Week 24 to Week 52/Extension Treatment Period of Placebo )

    Drug: HMI-115

  • Placebo comparator
    Placebo

    2ml , Once Every 2 weeks, subcutaneously injection,total of 12 injections (Week 0 to Week 24)

    Drug: Placebo

Interventions

  • HMI-115 is human monoclonal antibody (120mg/vail)

  • DrugPlacebo

    Placebo (0mg/vail)

06

What researchers measure

Primary outcomes

  1. Change from Baseline (CFB) in dysmenorrhea (DYS) measured by Numeric Rating Scale (NRS) at Week 12

    Time frame: week 12

  2. CFB in non-menstrual pelvic pain (NMPP) measured by NRS at Week 12

    Time frame: week 12

Secondary outcomes

  1. CFB in DYS measured by NRS at Week 24

    Time frame: week 24

  2. CFB in NMPP measured by NRS at Week 12

    Time frame: week 24

  3. CFB in average overall pelvic pain measured by NRS at Week 12 and week 24

    Time frame: Week 12 and week 24

  4. CFB in DYSP measured by NRS at Week 12 and week 24

    Time frame: Week 12 and week 24

  5. Changes in the number of remedial analgesics allowed to be used compared to baseline

    Time frame: Week 12 and week 24

  6. Adverse Events

    64 Weeks

    Time frame: During the clinical study period

  7. To investigate the pharmacokinetics (PK) characteristic of HMI-115, Serum trough concentrations at each time point and descriptive statistics.

    Serum trough concentrations at each time point and descriptive statistics.

    Time frame: Before the first intervention、Week 2、Week 4、Week 8、Week 12、Week 16、Week 20、Week 24、Week 32、Week 40、Week 52

  8. To investigate the immunogenicity of HMI-115:Anti-drug antibody (ADA) and Neutralizing antibody (NABs)

    Time frame: Before the first intervention、Week 2、Week 4、Week 8、Week 12、Week 16、Week 20、Week 24、Week 32、Week 40、Week 52

07

Study locations

1 of 5 sites recruiting
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100703, China
    Not yet recruiting
    • Zhu Lan, Ph.D. · Contact
  • Nanjing Women and children's healthcare hospital
    Nanning, Jiangsu, China
    Not yet recruiting
    • Ruan Hongjie · Contact
  • Second Affiliated Hospital of Soochow University
    Suzhu, Jiangsu, China
    Recruiting
    • Zhu Weipei · Contact
  • The International Peace Maternity and Child Health Hospital of the China Welfare Institute
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
    • Xu Hong · Contact
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality, China
    Not yet recruiting
    • Xue Fengxia · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.

Of 33 phase 3 interventional studies under Endometriosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2025
First posted
Jan 6, 2026
StartActual
Jan 29, 2026
Primary completionEst.
Mar 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07318688
Lead sponsor
Hope Medicine (Nanjing) Co., Ltd
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Jan 29, 2026
Primary completion
Mar 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

Xu Yeqing
Contact
yeqing.xu@hopemedinc.com
86-18717858198

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HMI-115

Start the discussion